July 17, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Vital Therapies Inc (NASDAQ:VTL) shares over potential securities laws violations by Vital Therapies Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vital Therapies Inc (NASDAQ:VTL) concerning whether a series of statements by Vital Therapies Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 14, 2015, a report was published alleging that Vital Therapies Incs representations regarding the 90 day overall survival rate for those treated with Vital Therapies Extracorporeal Liver Assist Device (ELAD) were highly misleading, as they allegedly included survival data from a patient who received a liver transplant, while no equivalent patient in the control group had received a transplant. The report alleged that this fact was not disclosed in any of the Companys prior disclosures concerning the Phase 2 VTI-206 study of ELAD.